Kalydeco Label Expansion Could Set New Precedent On FDA Flexibility
Executive Summary
Agency must decide whether to approve for cystic fibrosis patients with R117H mutation even though the pivotal trial failed and age-related subgroup analyses produced conflicting results. Vertex picked up an advisory committee endorsement despite panelists’ concerns about suboptimal results in pediatric patients.